| Drug General Information |
| Drug ID |
D0V6EV
|
| Former ID |
DIB004614
|
| Drug Name |
PF-4554878
|
| Synonyms |
PF-04554878; PF-941222; FAK inhibitors (cancer), Pfizer
|
| Drug Type |
Small molecular drug
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 1 |
[1],
[2]
|
|---|
| Company |
Pfizer Inc
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C20H21F3N8O3S
|
| InChI |
InChI=1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)
|
| InChIKey |
FWLMVFUGMHIOAA-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
56441315, 81003321, 137394508, 138584885, 173334228, 194175385, 198950697, 223705438, 227818254, 249099555, 249565593, 249715017, 252451785, 252471356
|
| Target and Pathway |
| Target(s) |
Focal adhesion kinase |
Target Info |
Inhibitor |
[3]
|
|---|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
Chemokine signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Axon guidance
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Leukocyte transendothelial migration
|
|
Regulation of actin cytoskeleton
|
|
Bacterial invasion of epithelial cells
|
|
Amoebiasis
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
Small cell lung cancer
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Integrin signalling pathway
|
|
VEGF signaling pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
CXCR4-mediated signaling events
|
|
Reactome
|
Apoptotic cleavage of cellular proteins
|
|
Regulation of actin dynamics for phagocytic cup formation
|
|
Integrin alphaIIb beta3 signaling
|
|
GRB2:SOS provides linkage to MAPK signaling for Integrins
|
|
p130Cas linkage to MAPK signaling for integrins
|
|
NCAM signaling for neurite out-growth
|
|
Signal regulatory protein (SIRP) family interactions
|
|
EPHB-mediated forward signaling
|
|
EPHA-mediated growth cone collapse
|
|
DCC mediated attractive signaling
|
|
Netrin mediated repulsion signals
|
|
VEGFA-VEGFR2 Pathway
|
|
RHO GTPases Activate WASPs and WAVEs
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
|
EGF/EGFR Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Focal Adhesion
|
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
JAK/STAT
|
|
Primary Focal Segmental Glomerulosclerosis FSGS
|
|
Alpha 6 Beta 4 signaling pathway
|
|
Corticotropin-releasing hormone
|
|
Leptin signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Netrin-1 signaling
|
|
NCAM signaling for neurite out-growth
|
|
Integrin-mediated Cell Adhesion
|
|
Integrin alphaIIb beta3 signaling
|
|
Apoptotic execution phase
|
|
Angiogenesis
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00787033) A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies. U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7910). |
|---|
| REF 3 | 567 A Novel Focal Adhesion Kinase Inhibitor (PF-04554878) Decreases Growth and Induces Apoptosis in Pancreatic Neuroendocrine Tumor Cells. Cancer Research. 06/2012; 72(8 Supplement):1921-1921. |
|---|
